July 12, 2024 — Reuters has a news flash for us. People are quick to quit taking GLP-1 medicines. In an “exclusive” story, the Reuters report comes from a analysis from Prime Therapeutics and Magellan Rx (Prime/MRx) – a pharmacy benefit manager (PBM). The headline finding is that 85% of people who start on GLP-1 medicines have quit taking […]
May 30, 2024 — In a world that systematically denies people access to obesity medicines, the rush of reports that people frequently stop taking them makes us wonder. How does this qualify as news? Why do reporters repeatedly paint a misleading picture of non-compliant patients? Yet, health reporters keep offering up this narrative. The latest prompt for this is […]
December 7, 2023 — It is mildly entertaining to watch people squirm as new obesity medicines disrupt their presumptions about obesity and its treatment. Of course, this squirming comes in many different forms. One expression of it is dismay that many people don’t keep taking obesity meds after a year. “Until compliance for these medications increases,” we’re not going […]
August 22, 2023 — A new study of real world primary non-adherence (PNA, not filling an Rx) for obesity medicines provides documentation for something that should surprise no one. More than 90% prescriptions for obesity meds are never filled. Writing in the Journal of Managed Care + Specialty Pharmacy, Hong Kan and colleagues say this is unusual, especially for […]
July 17, 2023 — A recent thread in the ongoing public discourse about new, advanced obesity medicines relates to how long people should take them and how long they actually do take them. The revelation that started this is data from a pharmacy benefit manager (PBM) indicating that two-thirds of patients typically stop taking them within a year. So […]
